Physician profile
Gary Tsai
NPI 1629495585
$2,055.79
in general payments reported to CMS, 2019-2025
30 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $117 · 2021: $201 · 2022: $140 · 2023: $287 · 2024: $430 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $363.08 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $306.44 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $262.67 | 2019-2025 | |
| Abbott Laboratories | $187.03 | 2023-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $107.22 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $56.01 | 2021 | |
| Amgen INC. | $50.78 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $46.36 | 2021-2024 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.54 | 2020-2021 | |
| Redhill Biopharma INC. | $43.39 | 2020 | |
| Novo Nordisk INC | $40.82 | 2022-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $36.83 | 2019-2021 | |
| Ucb, INC. | $28.33 | 2024 | Briviact |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $27.62 | 2025 | Alvesco |
| Paratek Pharmaceuticals, INC. | $23.74 | 2023 | Nuzyra |
| Harmony Biosciences LLC | $23.60 | 2024 | |
| Phadia US INC. | $23.27 | 2024 | Immunocap |
| Tetraphase Pharmaceuticals, INC. | $22.93 | 2019 | |
| Abbvie INC. | $22.50 | 2021 | |
| Exact Sciences Corporation | $19.67 | 2023 | Cologuard Collection Kit |
| Braeburn INC. | $17.83 | 2024 | Brixadi |
| Shield Therapeutics INC | $17.32 | 2022 | |
| Hologic Sales and Service, LLC | $16.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.41 | 2023 | |
| Insulet Corporation | $16.02 | 2025 | Omnipod |
| Nabriva Therapeutics, Plc | $14.95 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.89 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.